Good News | Leadingpharm (Chongqing) Successfully Selected as a Supporting Entity for the Chongqing Municipal Science and Technology Bureau’s Proof‑of‑Concept Center

Recently, the official website of the Chongqing Municipal Science and Technology Bureau published the “Notice on the List of Proof‑of‑Concept Centers Established by the Chongqing Municipal Science and Technology Bureau.” Leadingpharm (Chongqing) Pharmaceutical Technology Co., Ltd. was successfully selected as a supporting entity for the “Chongqing Municipal Science and Technology Bureau Small Molecule Targeted Drug Proof‑of‑Concept Center.”
 

The Chongqing Small Molecule Targeted Drug Proof‑of‑Concept Center is jointly established by the School of Pharmacy / International Institute of Innovative Targeted Drug Discovery at Chongqing University of Arts and Sciences, Leadingpharm (Chongqing) Pharmaceutical Technology Co., Ltd., and Dashu Bioengineering (Chongqing) Co., Ltd. Guided by the national and Chongqing municipal bio‑pharmaceutical industry development plans, the center focuses on the entire value chain of small‑molecule drug R&D, drug registration, clinical CRO, CDMO, and MAH. It conducts joint research across multiple levels—including drug feasibility studies, drug design and synthesis, in vivo/in vitro activity evaluation, CRO, CDMO, and MAH—to promote the clinical translation of validated projects. The center is committed to becoming a theoretical innovation platform, technology R&D platform, achievement transformation platform, and open service platform for innovative drug development in Chongqing.
 

Proof‑of‑concept and pilot‑scale development are critical steps in the transformation and industrialization of scientific and technological achievements, and they serve as important bridges between technological innovation and industrial innovation. The establishment of the Chongqing Small Molecule Targeted Drug Proof‑of‑Concept Center aims to accelerate the process and quality of new drug R&D and clinical research coverage in the Chengdu‑Chongqing region, stimulate innovation vitality in the bio‑pharmaceutical field, promote deep integration of technology and economy, expedite the development of Chongqing’s bio‑pharmaceutical industry, and contribute to the region’s economic and social development—carrying strategic significance and broad social benefits.
 

Leadingpharm (Chongqing)’s successful selection as a supporting entity for the Proof‑of‑Concept Center is a recognition of the company’s professionalism, innovation capacity, and growth potential. In the future, the company will closely align with Chongqing’s “416” technology innovation layout and “33618” modern manufacturing cluster system, uphold the corporate vision of “Let China’s new drug technology and production processes keep pace with the world,” strengthen its service capabilities in small‑molecule targeted drug proof‑of‑concept, and advance the integrated development of technological innovation and industrial innovation in the pharmaceutical industry.

-END-